Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319
about
Fibroblast Growth Factor Signaling in Metabolic RegulationMetabolic Effects of FGF-21: Thermoregulation and BeyondInventing new medicines: The FGF21 storyHuman FGF-21 Is a Substrate of Fibroblast Activation ProteinThe Role and Potential Therapeutic Implications of the Fibroblast Growth Factors in Energy Balance and Type 2 Diabetes.Metabolic role of fibroblast growth factor 21 in liver, adipose and nervous system tissues.Discovery of Novel Insulin Sensitizers: Promising Approaches and Targets.Reduced adiposity attenuates FGF21 mediated metabolic improvements in the Siberian hamster.Autophagy and non-alcoholic fatty liver disease.LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic MonkeysFibroblast growth factor 21 improves insulin sensitivity and synergizes with insulin in human adipose stem cell-derived (hASC) adipocytes.Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin-deficient obese miceFibroblast growth factor 21 is elevated in metabolically unhealthy obesity and affects lipid deposition, adipogenesis, and adipokine secretion of human abdominal subcutaneous adipocytes.FGF21 does not require interscapular brown adipose tissue and improves liver metabolic profile in animal models of obesity and insulin-resistance.Minireview: Roles of Fibroblast Growth Factors 19 and 21 in Metabolic Regulation and Chronic DiseasesCirculating FGF21 proteolytic processing mediated by fibroblast activation protein.Fibroblast Activation Protein Cleaves and Inactivates Fibroblast Growth Factor 21PF-05231023, a long-acting FGF21 analogue, decreases body weight by reduction of food intake in non-human primates.FGF21 mimetic shows therapeutic promise.An engineered FGF21 variant, LY2405319, can prevent non-alcoholic steatohepatitis by enhancing hepatic mitochondrial function.FGF21 is not required for glucose homeostasis, ketosis or tumour suppression associated with ketogenic diets in mice.New perspectives on the development of antiobesity drugs.Latest approaches for the treatment of obesity.Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23.A Comprehensive Review of Novel Drug-Disease Models in Diabetes Drug Development.Fibroblast Growth Factor 21 As an Emerging Therapeutic Target for Type 2 Diabetes Mellitus.Targeting adipose tissue in the treatment of obesity-associated diabetes.Fibroblast growth factor 21 night watch: advances and uncertainties in the field.Fibroblast Growth Factor 21 Mimetics for Treating Atherosclerosis.Fibroblast activation protein (FAP) as a novel metabolic target.Effects of fibroblast growth factor 21 on cell damage in vitro and atherosclerosis in vivo.Prokaryotic soluble expression and purification of bioactive human fibroblast growth factor 21 using maltose-binding protein.Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates.Process development of a FGF21 protein-antibody conjugate.LY2405319, an analog of fibroblast growth factor 21 ameliorates α-smooth muscle actin production through inhibition of the succinate-G-protein couple receptor 91 (GPR91) pathway in mice.Structures of β-klotho reveal a 'zip code'-like mechanism for endocrine FGF signalling.Glyco-engineered Long Acting FGF21 Variant with Optimal Pharmaceutical and Pharmacokinetic Properties to Enable Weekly to Twice Monthly Subcutaneous Dosing.Fusion of fibroblast growth factor 21 to a thermally responsive biopolymer forms an injectable depot with sustained anti-diabetic action.Insulin sensitizes FGF21 in glucose and lipid metabolisms via activating common AKT pathway.
P2860
Q26772751-373D68ED-ADDE-444D-9DED-AAF239294837Q26781427-4F0F92BA-76A3-4A32-AEDB-650A991CA1CDQ26823319-4C2AD2C1-79E8-490F-9C09-EE5BEDC2AFE0Q28550659-06B12879-6857-4515-899A-F121042FB915Q30234616-B188540F-E4DD-44E6-876B-63112ADC76E3Q33685319-5CB1729D-4A5B-4BF0-A5D2-2F5F50FECD42Q33808884-B85758F8-6798-46AF-8F72-9D405B04016BQ33835303-D356F1BC-AF83-48D4-9F5E-7D106B92A528Q34247340-EEEB3D74-CC12-4FFD-A7D0-66B27DFDEA0EQ34792753-65442343-A0B5-46A3-AFDC-9949D204E33AQ35387801-2D40DC13-0220-4676-9F0C-B387B586802AQ35581474-BF5CA6F3-DD77-4283-AA29-9636D4421F54Q35784028-8D4D23FA-4534-4B62-9AA0-744BAA6CB0BDQ35830589-790C33CC-2E15-4B49-B6F4-DC4F4A0F53FAQ36107291-256990B9-1CA0-4303-81EF-B8F82D7D8CA6Q36611366-09C7473B-CBEA-46A7-9E71-B3873437E2A3Q36674741-04FA517F-A3C3-4BE8-8244-349E156450A6Q37112476-088C229A-709B-4051-832F-41B2B1B37420Q37211913-BCA12057-6C0D-4848-81E7-ECB7048A8459Q37448127-EC627B32-1425-4864-B468-5930184700B5Q37485018-EC7ED4A5-0340-4509-A1B9-400549A67A81Q38397340-C18DC98F-0F10-4C86-ABDA-6A54F371047AQ38475978-55A08C51-5FC1-4181-9928-99392B14C646Q38633258-AB2356A5-67E1-44F3-B684-E235CB3DBBFEQ38707493-B65CC887-5444-4210-885E-C4B9C8734499Q38794405-A726A544-AE25-4F8D-AB85-9777B5A61E92Q38852204-9BB5A83C-68E1-42FA-BE30-3DC0927827F9Q39017842-07E3C3F1-B5EE-4F6D-9974-81CA782552C9Q39325845-0CE1CA7C-0F68-47F0-A8A0-1F00AAE6C3B0Q41166927-76D2C2D7-2ABF-4C28-973B-D6FEEEB45D73Q43639041-0F9C7BBD-2C95-4D5E-B51A-06EFA82BA733Q47151186-F688E43F-900C-45FD-8FE4-03BCB3E62D4FQ47209022-395F1876-26EB-4D3A-8061-E8144B1D03D0Q47742925-D5CFB9D9-739A-4F9D-9FA8-BB5E8A49E794Q50000450-A9C966B8-15F9-4359-8624-6ECE3D5B1567Q50001768-04B1E53F-161E-4714-8E1B-6DA645B8BB23Q51730495-191EF85A-BA23-4316-B839-D09C18C02408Q52649955-108C6CEA-44ED-4C4F-9F4A-D09EDBD829C6Q53807997-0E19CC83-7D21-4A6A-A34B-6746A23F24E4
P2860
Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319
@ast
Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319
@en
Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319
@nl
type
label
Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319
@ast
Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319
@en
Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319
@nl
prefLabel
Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319
@ast
Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319
@en
Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319
@nl
P2093
P2860
P3181
P1433
P1476
Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319
@en
P2093
Alexei Kharitonenkov
Amy M Ford
Anja Koester
Beth A Strifler
Christine C Cheng
Christopher C Frye
David E Moller
James D Dunbar
John M Beals
Radhakrishnan Rathnachalam
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0058575
P407
P577
2013-01-01T00:00:00Z